Application No.: 10/797,367

Amendment Dated: March 31, 2009

Reply to Office Action Mailed: October 31, 2008

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-27 (Canceled).

Claim 28 (Currently amended): A composition suitable for local, non-systemic administration of a drug to a body and directly to tissue within a body cavity having been subjected to a surgical procedure, said composition comprising a delivery vehicle consisting of Tranilast or an analog thereof selected from the group consisting of N-(2-Acetyl-4,5-dimethoxyphenyl)(4-((phenylamino)carbonylamino)phenyl)formamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-2-(4-((phenylamino)-carbonylamino)phenyl)ethanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((phenylamino)-carbonylamino)phenyl)prop-2-enamide. N-(2-Acetyl-4.5dimethoxyphenyl)-3-(4-((phenylamino)-carbonylamino)phenyl-)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-4-(4-((phenylamino)carbonyl-amino)phenyl) butanamide. N-(2-Acetyl-4.5-dimethoxyphenyl)-3-(4-(phenylcarbonvlamino) carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphen-yl)-3-(4-(2phenylacetylamino)phenyl)propanamide, N-(2-Acetyl-4.5-dimethox- yphenyl)-3-(4-(phenoxycarbonylamino)phenyl)propanamide, N-(2-Acetyl-4.5dimethoxyphenyl)-3-(4-(((2-nitrophenyl)amino)carbonylamino)phenyl)propanamide. N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3-nitrophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl-)-3-(4-(((4-nitrophenyl)amino)carbonylamino)phenyl)propanamide. N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((2-aminophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3-aminophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenylApplication No.: 10/797,367

Amendment Dated: March 31, 2009

Reply to Office Action Mailed: October 31, 2008

)-3-(4-(((4-aminophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4.5-dimethoxyphenyl)-3-(4-(((4-fluorophenyl)amino)carbonylami-

no)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-acetylphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4.5-dimethoxyphenyl)-3-(4-(((4-methylphenyl)amino)carbonylamino)phenyl)propanamide. N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-methoxyphenyl)amino)carbonylamino)phenyl)propanamide. N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3,4,5-trimethoxyphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4.5dimethoxyphenyl)-3-(4-(((4-pyridyl)amino)carbonylamino)ph-enyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((benzylamino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((buty-1 amino)carbonylamino)phenyl)propanamide, and N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((cyclohexylamino)carbonylamino)phenyl)propanamide. and the

yl)-3-(4-((cyclohexylamino)carbonylamino)phenyl)propanamide, and the potassium, sodium, calcium and magnesium salts of Tranilast, in an amount effective to inhibit formation of post-operative adhesions upon local, non-systemic administration of said composition to said tissue, and in a biodegradable polymer earrier in a form selected from the group consisting of film, foam, fibers and filaments, suitable for local, non-systemic administration of said Tranilast or analog thereof.

Claim 29. (Canceled).

Claim 30. (Currently amended) The composition of claim 28 wherein said biodegradable earrier-comprises a polymer is selected from the group consisting of poloxamers, poly(orthoester)s, poly(inyl_alcohol)s, poly(anhydride)s, poly(methacrylate)s, poly(methacrylamide)s, anionic carbohydrate polymers, poly(hydroxybutyric acid)s, polyacetals, poly(1-lactide), poly(dl-lactide), poly(dl-lactide), poly(e-caprolactone), polyglycolide, poly(p-dioxanone)s, poly(trimethylene carbonate), poly(alkylene diglycolate)s, poly(oxaester)s, poly(oxaemide)s and divceride polymers.

Application No.: 10/797,367

Amendment Dated: March 31, 2009

Reply to Office Action Mailed: October 31, 2008

Claim 31 (Original): The composition of claim 28 wherein said composition

provides for single dose administration of said Tranilast or analog thereof.

Claim 32 (Currently amended): The composition of claim 28 wherein said

composition provides for sustained release of said is Tranilast or analog thereof.

Claim 33 (Canceled).

Claim 34 (Original): The composition of claim 28 comprising from about 0.01

milligram Tranilast or analog thereof per kilogram of the body to about 3,000

milligram Tranilast or analog thereof per kilogram of the body.

Claim 35-38 (Canceled).

Claim 39 (Currently amended): The composition of claim 28 wherein said

biodegradable polymer is comprises a material selected from the group consisting of hyaluronic acids, collagens, pluronics, chitin, chitosans, dextrans,

glucoses, carbohydrates, gelatins, glycosaminoglycans, aliginates, starches and

polypeptides.

Claim 40 (Previously presented): The composition of claim 28 further comprising

a therapeutic agent in an amount effective to provide the therapeutic effect

intended by administration of said therapeutic agent.

Claim 41 (Previously presented): The composition of claim 40 wherein said

therapeutic agent is selected from the group consisting of an anti-platelet, an

anti-fibrotic, an anti-inflammatory, an anti-proliferative and an agent that inhibits

collagen synthesis.

4